DR_SEQAN:: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes

被引:11
|
作者
Garriga, C [1 ]
Menéndez-Arias, L [1 ]
机构
[1] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain
关键词
D O I
10.1186/1471-2334-6-44
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Genotypic assays based on DNA sequencing of part or the whole reverse transcriptase (RT)- and protease (PR)-coding regions of the human immunodeficiency virus type 1 (HIV-1) genome have become part of the routine clinical management of HIV-infected individuals. However, the results are difficult to interpret due to complex interactions between mutations found in viral genes. Results: DR_SEQAN is a tool to analyze RT and PR sequences. The program output includes a list containing all of the amino acid changes found in the query sequence in comparison with the sequence of a wild-type HIV-1 strain. Translation of codons containing nucleotide mixtures can result in potential ambiguities or heterogeneities in the amino acid sequence. The program identifies all possible combinations of 2 or 3 amino acids that derive from translation of triplets containing nucleotide mixtures. In addition, when ambiguities affect codons relevant for drug resistance, DR_SEQAN allows the user to select the appropriate mutation to be considered by the program's drug resistance interpretation algorithm. Resistance is predicted using a rule-based algorithm, whose efficiency and accuracy has been tested with a large set of drug susceptibility data. Drug resistance predictions given by DR_SEQAN were consistent with phenotypic data and coherent with predictions provided by other publicly available algorithms. In addition, the program output provides two tables showing published drug susceptibility data and references for mutations and combinations of mutations found in the analyzed sequence. These data are retrieved from an integrated relational database, implemented in Microsoft Access, which includes two sets of non-redundant core tables (one for combinations of mutations in the PR and the other for combinations in the RT). Conclusion: DR_SEQAN is an easy to use off-line application that provides expert advice on HIV genotypic resistance interpretation. It is coded in Visual Basic for use in PC/Windows-based platforms. The program is freely available under the General Public License. The program (including the integrated database), documentation and a sample sequence can be downloaded from http://www2.cbm.uam.es:8080/Imenendez/DR_SEQAN.zip
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance
    Zahm, Jacob A.
    Bera, Sibes
    Pandey, Krishan K.
    Vora, Ajaykumar
    Stillmock, Kara
    Hazuda, Daria
    Grandgenett, Duane P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) : 3358 - 3368
  • [32] The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions
    Cong, Mian-er
    Heneine, Walid
    Garcia-Lerma, J. Gerardo
    JOURNAL OF VIROLOGY, 2007, 81 (06) : 3037 - 3041
  • [33] Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates
    Campo, RE
    Lichtenberger, PN
    Rosa, I
    Suarez, G
    Rivera, FA
    Rodriguez, AE
    Jayaweera, DT
    Wahlay, NA
    Kolber, MA
    JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (07) : 3376 - 3378
  • [34] Prevalence, Molecular Epidemiology and Drug Resistance Pattern of Human Immunodeficiency Virus Type 1 among Injecting Drug Users in Lahore, Pakistan
    Yaqub, Saima
    Yaqub, Tahir
    Shabbir, Muhammad Zubair
    Nadeem, Asif
    Aziz-Ul-Rahman
    Shahid, Muhammad Furqan
    Tahir, Zarfishan
    Mukhtar, Nadia
    PAKISTAN JOURNAL OF ZOOLOGY, 2021, 53 (02) : 563 - 572
  • [35] Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus
    Gandhi, RT
    Wurcel, A
    Rosenberg, ES
    Johnston, MN
    Hellmann, N
    Bates, M
    Hirsch, MS
    Walker, BD
    CLINICAL INFECTIOUS DISEASES, 2003, 37 (12) : 1693 - 1698
  • [36] Impact of nucleotide polymorphisms at drug resistance sites on genetic barrier in human immunodeficiency virus type 1 subtype C resistance evolution
    Iweriebor, Benson Chuks
    Masebe, Tracy
    Nwobegahay, Julius
    Mphahlele, Jeffrey M.
    Bessong, Pascal Obong
    AFRICAN JOURNAL OF BIOTECHNOLOGY, 2011, 10 (68): : 15320 - 15326
  • [37] Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
    de la Carrière, LC
    Paulous, S
    Clavel, F
    Mammano, F
    JOURNAL OF VIROLOGY, 1999, 73 (04) : 3455 - 3459
  • [38] Novel enzyme-linked minisequence assay for genotypic analysis of human immunodeficiency virus type 1 drug resistance
    Sugiura, W
    Shimada, K
    Matsuda, M
    Chiba, T
    Myint, L
    Okano, A
    Yamada, K
    JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (11) : 4971 - 4979
  • [39] DEVELOPMENT AND SIGNIFICANCE OF NUCLEOSIDE DRUG-RESISTANCE IN INFECTION CAUSED BY THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    SMITH, M
    SALOMON, W
    WAINBERG, MA
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1994, 17 (03): : 226 - 243
  • [40] Impact of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Drug Resistance Mutation Interactions on Phenotypic Susceptibility
    Trivedi, Vinod
    Von Lindern, Jana
    Montes-Walters, Miguel
    Rojo, Daniel R.
    Shell, Elisabeth J.
    Parkin, Neil
    O'Brien, William A.
    Ferguson, Monique R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 (10) : 1291 - 1300